Investigational Drug Information for AT-527
✉ Email this page to a colleague
What is the development status for investigational drug AT-527?
AT-527 is an investigational drug.
There have been 23 clinical trials for AT-527.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 25th 2022.
The most common disease conditions in clinical trials are COVID-19, Hepatitis C, Chronic, and Hepatitis C. The leading clinical trial sponsors are Atea Pharmaceuticals, Inc., Hoffmann-La Roche, and [disabled in preview].
There are six US patents protecting this investigational drug and sixty-eight international patents.
Summary for AT-527
| US Patents | 6 |
| International Patents | 68 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2022-11-25) |
| Vendors | 17 |
Recent Clinical Trials for AT-527
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV | Atea Pharmaceuticals, Inc. | Phase 2 |
| The Study of Bemnifosbuvir in Healthy Japanese Subjects | Atea Pharmaceuticals, Inc. | Phase 1 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects | Atea Pharmaceuticals, Inc. | Phase 1 |
Clinical Trial Summary for AT-527
Top disease conditions for AT-527
Top clinical trial sponsors for AT-527
US Patents for AT-527
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AT-527 | ⤷ Sign Up | .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| AT-527 | ⤷ Sign Up | .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'.beta.-C-substituted-2-modified-N.su- p.6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| AT-527 | ⤷ Sign Up | Beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substi- tuted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| AT-527 | ⤷ Sign Up | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| AT-527 | ⤷ Sign Up | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n.s- up.6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| AT-527 | ⤷ Sign Up | .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AT-527
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AT-527 | Australia | AU2016229966 | 2035-03-06 | ⤷ Sign Up |
| AT-527 | Australia | AU2018282469 | 2035-03-06 | ⤷ Sign Up |
| AT-527 | Australia | AU2020203055 | 2035-03-06 | ⤷ Sign Up |
| AT-527 | Australia | AU2021204022 | 2035-03-06 | ⤷ Sign Up |
| AT-527 | Australia | AU2023202634 | 2035-03-06 | ⤷ Sign Up |
| AT-527 | Brazil | BR112017018977 | 2035-03-06 | ⤷ Sign Up |
| AT-527 | Canada | CA2978085 | 2035-03-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
